Previous close | 9.20 |
Open | N/A |
Bid | 3.50 |
Ask | 7.50 |
Strike | 70.00 |
Expiry date | 2024-06-21 |
Day's range | 9.20 - 9.20 |
Contract range | N/A |
Volume | |
Open interest | 286 |
Immunocore Holdings plc ( NASDAQ:IMCR ) shareholders are probably feeling a little disappointed, since its shares fell...
Comprehensive Analysis of Immunocore's Financial Performance and Strategic Updates
Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $70.3 million in Q1 2024; continuing to expand global access with 7 additional launches since January 2024 Phase 1/2 brenetafusp (IMC-F106C; PRAME-A02) clinical data in post-checkpoint late-line cutaneous melanoma selected for oral presentation at ASCO 2024 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, May 8, 2024) Immunocore Holdings plc (Nasdaq: IMC